Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/39386
Title: | Epstein-Barr virus encephalitis in solid organ transplantation. | Authors: | Kitching A.R. ;Kanellis J.;Korman T. ;Lau J.S.Y.;Low Z.M.;Abbott I.;Shochet L. | Monash Health Department(s): | Infectious Diseases and Clinical Microbiology Nephrology |
Institution: | (Lau, Low, Korman) Monash Infectious Diseases, Monash Health, Clayton, VIC, Australia (Abbott) Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia (Shochet, Kanellis, Kitching, Korman) Departments of Nephrology and Paediatric Nephrology, Monash Health, Clayton, VIC Australia (Kitching) Centre for Inflammatory Diseases, Monash University Department of Medicine, Clayton, VIC, Australia | Issue Date: | 22-Jan-2018 | Copyright year: | 2017 | Place of publication: | Italy | Publication information: | The new microbiologica. 40 (3) (pp 212-217), 2017. Date of Publication: 01 Jul 2017. | Abstract: | Epstein-Barr virus (EBV) is typically associated with post transplant lymphoproliferative disease (PTLD) after solid organ and stem cell transplantation. However, it is rarely associated with neurological complications. We report a case of severe encephalitis complicating primary EBV infection six months post renal transplantation, and review the literature on EBV encephalitis in solid organ transplantation in adults. A 55-year-old male presented 6 months post cadaveric renal transplant with headache, fever and confusion. Neuroimaging was unremarkable, but an electroencephalogram was consistent with diffuse encephalopathy. EBV DNA was detected in both cerebrospinal fluid (13,177 copies/ml), and plasma (14,166 copies/ml). Management included reduction of immunosuppression, intravenous ganciclovir and intravenous immunoglobulin, and resulted in a reduction in EBV viral load in both plasma and cerebrospinal fluid. The patient made a full recovery with no long-term neurological deficits and preservation of the graft. This case highlights the importance of knowing donor and recipient EBV serostatus at time of transplant, and closely monitoring EBV DNA when there is a mismatch. Ganciclovir or valganciclovir prophylaxis has also been shown to reduce the incidence of primary EBV infection in renal transplantation in these recipients. Treatment options for EBV infection post-transplant include reduction of immunosuppression, antiviral therapy, IVIg, and monoclonal antibody therapy directed toward infected B lymphocytes. | PubMed URL: | 28513810 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28513810] | ISSN: | 1121-7138 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/39386 | Type: | Article | Type of Clinical Study or Trial: | Case series or case report |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.